Shane Schaffer

Shane Schaffer, Co-founder, Chairman, and CEO of Cingulate Therapeutics in Kansas City, Kansas, leads the Phase 3 clinical-stage biopharmaceutical company known for its advanced pharmaceutical products, especially those for Attention Deficit/Hyperactivity Disorder (ADHD), anxiety disorders, and insomnia.

With a 25-year track record in pharmaceuticals, he is an expert in drug development and commercialization. His roles across product launches, brand planning, joint ventures, life cycle management, and market development have distinguished him in biopharmaceutical and marketing.

After earning his doctoral degree in Pharmacy from the University of Kansas in 1999, he furthered his expertise with a postdoctoral fellowship at Rutgers University's College of Pharmacy, during which he contributed to projects at Pfizer Worldwide Marketing and Morris Plains.

While with Pfizer in New York, he spearheaded pre-launch strategies and was instrumental in developing a Global Communications Intranet. In New Jersey, he served as Project Manager and External Research Manager, leading advanced sales training and overseeing Phase IV Medical Research for all marketed brands.

Throughout his career, he held leadership roles at Pfizer, Novartis, and Sanofi, where he developed and commercialized multi-billion-dollar brands. At Novartis, he managed the Ritalin® LA and Focalin™ segments, launching these products with substantial market success and fostering remarkable product awareness shortly thereafter. His efforts garnered him multiple awards, including the Novartis Business Excellence Award.

After Novartis, his career continued at Sanofi, where his strategic leadership significantly impacted the company during critical merger and joint venture phases, particularly with brands like Avapro and Avalide. His role was pivotal in developing and implementing comprehensive promotional campaigns and sales strategies.

In 2008, he joined M|C Communications LLC as a Consultant, leading the development of business opportunities for primary pharmaceutical targets. He founded Sabre Scientific Solutions, LLC in 2009, offering consulting services to the pharmaceutical and biotech industries, emphasizing commercial strategies, clinical management, and product launches.